MX2022011079A - Composiciones sinergicas y dirigidas para el tratamiento de trombosis arterial y venosa. - Google Patents
Composiciones sinergicas y dirigidas para el tratamiento de trombosis arterial y venosa.Info
- Publication number
- MX2022011079A MX2022011079A MX2022011079A MX2022011079A MX2022011079A MX 2022011079 A MX2022011079 A MX 2022011079A MX 2022011079 A MX2022011079 A MX 2022011079A MX 2022011079 A MX2022011079 A MX 2022011079A MX 2022011079 A MX2022011079 A MX 2022011079A
- Authority
- MX
- Mexico
- Prior art keywords
- synergistic
- arterial
- treatment
- venous thrombosis
- targeting compositions
- Prior art date
Links
- 230000002195 synergetic effect Effects 0.000 title abstract 2
- 206010003178 Arterial thrombosis Diseases 0.000 title 1
- 206010047249 Venous thrombosis Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 102000000412 Annexin Human genes 0.000 abstract 1
- 108050008874 Annexin Proteins 0.000 abstract 1
- 102000007347 Apyrase Human genes 0.000 abstract 1
- 108010007730 Apyrase Proteins 0.000 abstract 1
- 230000002785 anti-thrombosis Effects 0.000 abstract 1
- 229960004676 antithrombotic agent Drugs 0.000 abstract 1
- 230000000740 bleeding effect Effects 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4721—Lipocortins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01004—Phospholipase A2 (3.1.1.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
- C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
- C12Y306/01005—Apyrase (3.6.1.5), i.e. ATP diphosphohydrolase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Las combinaciones de una apirasa y una anexina, incluyendo proteínas de fusión de las mismas, son antitrombóticos sinérgicos que no inducen sangrado indeseado.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062986006P | 2020-03-06 | 2020-03-06 | |
PCT/EP2021/055558 WO2021176038A1 (en) | 2020-03-06 | 2021-03-05 | Synergistic and targeting compositions for treatment of arterial and venous thrombosis |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022011079A true MX2022011079A (es) | 2023-02-27 |
Family
ID=74859465
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022011079A MX2022011079A (es) | 2020-03-06 | 2021-03-05 | Composiciones sinergicas y dirigidas para el tratamiento de trombosis arterial y venosa. |
Country Status (16)
Country | Link |
---|---|
US (1) | US20230119254A1 (es) |
EP (1) | EP4114443A1 (es) |
JP (1) | JP2023516196A (es) |
KR (1) | KR20220150933A (es) |
CN (1) | CN115243710A (es) |
AR (1) | AR122391A1 (es) |
BR (1) | BR112022017821A2 (es) |
CA (1) | CA3173750A1 (es) |
CL (1) | CL2022002406A1 (es) |
CO (1) | CO2022013678A2 (es) |
CR (1) | CR20220503A (es) |
EC (1) | ECSP22077003A (es) |
IL (1) | IL295998A (es) |
MX (1) | MX2022011079A (es) |
TW (1) | TW202146042A (es) |
WO (1) | WO2021176038A1 (es) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7247300B1 (en) | 2002-11-07 | 2007-07-24 | Apt Therapeutics, Inc. | Therapeutic use of soluble CD39L3 |
EP2133430B1 (en) * | 2004-02-27 | 2014-12-17 | APT Therapeutics, Inc. | Design and therapeutic use of adpase enhanced apyrases |
PL1755642T3 (pl) * | 2004-04-15 | 2010-06-30 | Athera Biotechnologies Ab | Aneksyna V do zapobiegania pękaniu blaszek miażdżycowych |
EP2421360B1 (en) | 2009-04-22 | 2014-05-07 | Lotus Bio (Nymphaea) Ltd. | A sperm separation system |
CA2787016C (en) | 2010-01-13 | 2018-01-23 | Apt Therapeutics, Inc. | Therapeutic apyrase constructs, apyrase agents, and production methods |
WO2011088231A1 (en) * | 2010-01-13 | 2011-07-21 | Apt Therapeutics, Inc. | Apyrase therapy for bleeding conditions |
GB2542391A (en) * | 2015-09-17 | 2017-03-22 | Annexin Pharmaceuticals Ab | Process of manufacture |
-
2021
- 2021-02-23 TW TW110106225A patent/TW202146042A/zh unknown
- 2021-03-05 IL IL295998A patent/IL295998A/en unknown
- 2021-03-05 CA CA3173750A patent/CA3173750A1/en active Pending
- 2021-03-05 MX MX2022011079A patent/MX2022011079A/es unknown
- 2021-03-05 EP EP21710268.0A patent/EP4114443A1/en active Pending
- 2021-03-05 CR CR20220503A patent/CR20220503A/es unknown
- 2021-03-05 AR ARP210100577A patent/AR122391A1/es unknown
- 2021-03-05 CN CN202180019344.5A patent/CN115243710A/zh active Pending
- 2021-03-05 BR BR112022017821A patent/BR112022017821A2/pt unknown
- 2021-03-05 US US17/905,540 patent/US20230119254A1/en active Pending
- 2021-03-05 JP JP2022552895A patent/JP2023516196A/ja active Pending
- 2021-03-05 WO PCT/EP2021/055558 patent/WO2021176038A1/en active Application Filing
- 2021-03-05 KR KR1020227034472A patent/KR20220150933A/ko active Search and Examination
-
2022
- 2022-09-05 CL CL2022002406A patent/CL2022002406A1/es unknown
- 2022-09-23 CO CONC2022/0013678A patent/CO2022013678A2/es unknown
- 2022-10-03 EC ECSENADI202277003A patent/ECSP22077003A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA3173750A1 (en) | 2021-09-10 |
IL295998A (en) | 2022-10-01 |
ECSP22077003A (es) | 2022-11-30 |
US20230119254A1 (en) | 2023-04-20 |
EP4114443A1 (en) | 2023-01-11 |
CO2022013678A2 (es) | 2022-10-11 |
KR20220150933A (ko) | 2022-11-11 |
CN115243710A (zh) | 2022-10-25 |
JP2023516196A (ja) | 2023-04-18 |
BR112022017821A2 (pt) | 2023-01-31 |
AU2021230101A1 (en) | 2022-11-03 |
CR20220503A (es) | 2022-11-30 |
AR122391A1 (es) | 2022-09-07 |
WO2021176038A1 (en) | 2021-09-10 |
CL2022002406A1 (es) | 2023-04-14 |
TW202146042A (zh) | 2021-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018003582A1 (es) | Composiciones para modular la expresión de c9orf72 (divisional solicitud 201702567) | |
BR112021022504A2 (pt) | Inibidores de autofagia de fenilaminopirimidina amida e métodos de uso dos mesmos | |
BR112021022576A2 (pt) | Inibidores de autofagia de heteroarilaminopirimidina amida e métodos de uso dos mesmos | |
MX2022013526A (es) | Degradadores de proteinas y usos de los mismos. | |
MX2022002938A (es) | Compuestos inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) cooperativos para metiltioadenosina (mta). | |
CR20200101A (es) | Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y métodos de uso de anticuerpos anti-cd39 | |
CL2018001152A1 (es) | Composiciones y métodos para el tratamiento del cáncer | |
CL2020003071A1 (es) | Proteínas de unión multiespecíficas y mejoras con estas | |
MX2019010040A (es) | Composiciones y métodos para el tratamiento del cáncer. | |
TR201901077T4 (tr) | Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar | |
MX2022009596A (es) | Anticuerpos anti-ror1 y composiciones. | |
BR112021019734A2 (pt) | Composições contendo brazeína | |
WO2020021477A3 (en) | Compositions and methods for treating the eye | |
MX2021011524A (es) | Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos. | |
CL2020003355A1 (es) | Proteínas inmunodominantes y fragmentos en esclerosis múltiple | |
BR112021025544A2 (pt) | Inibidores de autofagia de aminopirimidina amida e métodos de uso dos mesmos | |
CL2021001903A1 (es) | Tratamiento de la hepatotoxicidad | |
MX2021009863A (es) | Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer. | |
CR20220503A (es) | Composiciones Sinérgicas Y Dirigidas Para El Tratamiento De Trombosis Arterial Y Venosa | |
MX2020009496A (es) | Metodo para tratar asma o enfermedad alergica. | |
EA202191058A1 (ru) | Антитела против муцина-16 и способы их применения | |
ZA202207539B (en) | Composition and methods of manufacture | |
MX2022011027A (es) | Composiciones y metodos para el tratamiento del cancer. | |
MX2021013117A (es) | Composiciones y metodos para el tratamiento del cancer. | |
MX2022003523A (es) | Proteinas de union a antigenos. |